Integrated Graph-Based Models Unveil Carbonic Anhydrase VIII, X, XI Expression in Cancer and Neurological Diseases.

The following repository consists of Python scripts and datasets associated with the overall work related to the manuscript: Integrated Graph-Based Models Unveil Carbonic Anhydrase VIII, X, XI Expression in Cancer and Neurological Diseases.

Carbonic anhydrases (CA) belong to the class of metalloenzymes that are known to exist among living organisms and are known for their catalytic activity in reversible reactions between carbon dioxide and water, leading to the exchange of carbonic acid constituents within the various cells and tissues of living organisms, specifically within human beings. Hence, CAs are responsible for maintaining overall balance along the respiratory and renal processes, maintaining acid-base balance, and regulating pH within the tissues and organs, respectively. While most of the CAs found within vertebrates are known to be active enzymes due to the presence of a zinc active site, a family of CAs known as CA-related proteins (CARPs) constitute the CA VIII, X, and XI (8, 10, and 11), respectively, which are enzymatically inactive due to their conformational changes leading to modification of histidine residues along the active site. However, research studies conducted across CARPs have shown that these specific CAs are found to be involved in cancer development across multiple organs and neurological disease pathways, with no potential studies regarding their details. Hence, in our manuscript, we present an end-to-end biological workflow utilizing various methodologies involving statistical procedures to compute similarity across the CARPs by assessing the occurrence of biological parameters shared across them and determining potential biomarkers in the form of transcription factors, coexpressed genes, and phenotypes, respectively, which could have possible expression levels to activate the CARPs activity along the disease pathways. Additionally, we proposed a One Health model by analyzing various drugs and chemical candidates that would have potential therapeutic effects in suppressing the biomarkers associated with disease development, hence providing a therapeutic response against the negative modulation of CARPs within humans.